Reported Earlier, Astellas' PADCEV In Combination With KEYTRUDA Approved By European Commission, For First-Line Treatment Of Advanced Urothelial Cancer

0.00%

ASTELLAS PHARMA

ALPMY

First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1
European Marketing Authorization based on positive overall survival and progression-free survival results from the global Phase 3 EV-302 trial1

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.